Loading
Life sciences · Journal article
Acs Applied Materials & Interfaces · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Clinical oncology faces a critical technological bottleneck driven by the rapid emergence of therapy-resistant tumors. Melanoma, in particular, remains a highly aggressive malignancy with pronounced metastatic potential and poor responsiveness to traditional therapy, signify the demand for advanced therapeutic strategies. Herein, we report a multifunctional nanoplatform integrating ternary layered double hydroxides (LDHs) with an injectable hydrogel system for localized and controlled melanoma therapy. The engineered trimetallic Cu–Zn–Fe LDHs (CZF) exhibit tunable physicochemical properties, enabling efficient drug intercalation, enhanced structural stability, and stimuli-responsive release within the tumor microenvironment. Doxorubicin (Dox) loaded LDHs (CZF@Dox) demonstrate high loading efficiency and sustained release, minimizing premature leakage and systemic toxicity. Computational insights from molecular dynamics and machine learning-assisted modeling reveal optimized host–guest interactions for improved delivery performance. In vitro studies confirm excellent biocompatibility toward normal 3T3-L1 cells (∼10% cell death at 20 μg/mL, 72 h), alongside significant cytotoxicity against B16F10 and SiHa cancer cells (∼80–85% cell death at the same conditions). In vivo evaluation further demonstrates effective tumor suppression with prolonged dosing intervals (96 h). Overall, this platform offers a predictive, minimally invasive, and efficient strategy for next-generation melanoma therapy.